When the causative pathogens are susceptible, the fluoroquinolones have bee
n demonstrated to be highly efficacious in the treatment of both mild uncom
plicated skin and skin structure infections as well as the more severe comp
licated infections involving these tissues, including infections of the fee
t of diabetic patients. These broad spectrum agents, particularly the newer
fluoroquinolones with enhanced activity against Gram-positive bacteria, ar
e ideal for treating the often polymicrobial complicated skin and skin stru
cture infections. The wisdom of treating uncomplicated skin infections, whi
ch are primarily due to staphylococci and streptococci wherein more narrow
spectrum p-lactam antibiotics would suffice, is questionable.